


CLAIMS

1. A compound according to formula (I):



wherein:

A³ is Acc, Act, or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Ile, Leu, Nle, Tie, hLeu, Cha, Val, Ala, Nva, and Abu, or the N-methylated variant of Acc, Act, or Aib, or of said D- or L- amino acid, or is deleted;

A⁴ is Aib, Acc, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Lys, Arg, hArg, Orn, Dab, Dap, and HN-CH((CH₂)_n-N(R⁴R⁵))-C(O), or the N-methylated variant of Aib, Acc, or Apc, or of said D- or L- amino acid, or is deleted;

A⁵ is Inc, or a D- or L- amino acid selected from the list of amino acids consisting of Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, and Oic, or the N-methylated variant of Inc or of said D- or L- amino acid, or is deleted;

A⁶ is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Glu, Asp, Gln, Asn, Lys, Arg, Orn, Dab, Dap, and hArg, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid, or is deleted;

A⁷ is Acc, Act, Aib, Apc, or Gly, or a D- or L- amino acid selected from the list of amino acids consisting of Ala, Abu, Val, and Nva, or the N-methylated variant of Acc, Act, Aib, Apc, or Gly, or of said D- or L- amino acid, or is deleted;

A⁸ is Inc or a D- or L- amino acid selected from the list of amino acids consisting of Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, and Oic, or the N-methylated variant of Inc or of said D- or L- amino acid, or is deleted;

A⁹ is Acc, Aib, or Gly, or D- or L- Ala, or the N-methylated variant of Acc, Aib, Gly, or D- or L- Ala, or is deleted;

A¹⁰ is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Glu, Asp, Gln, and Asn, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid, or is deleted;

A¹¹ is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Asp, Glu, Gln, and Asn, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid, or is deleted;

A¹² is Acc, Act, Aib, Apc, or Gly, or a D- or L- amino acid selected from the list of amino acids consisting of Ala, Abu, Val, and Nva, or the N-methylated variant of Acc, Act, Aib, Apc, or Gly, or of said D- or L- amino acid, or is deleted;

A¹³ is Acc, Aib, or Act, or a D- or L- amino acid selected from the list of amino acids consisting of Ser, Thr, Ala, Abu, and Val, or the N-methylated variant of Acc, Aib, or Act, or of said D- or L- amino acid, or is deleted;

A¹⁴ is Inc or a D- or L- amino acid selected from the list of amino acids consisting of Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, and Oic, or the N-methylated variant of Inc or of said D- or L- amino acid, or is deleted;

A¹⁵ is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Glu, Asp, Gln, and Asn, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid, or is deleted;

A¹⁶ is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Glu, Asp, Gln, and Asn, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid, or is deleted;

A¹⁷ is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Leu, Ile, Nle, Tle, hLeu, Cha, Val, Ala, Nva, Abu, and Phe, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid, or is deleted;

A¹⁸ is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Asn, Gln, Glu, and Asp, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid, or is deleted;

A¹⁹ is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Arg, hArg, Lys, Orn, Dab, Dap, and $\text{HN-CH}((\text{CH}_2)_n\text{-N(R}^4\text{R}^5))\text{-C(O)}$, or the N-methylated variant of Acc, Aib, or Apc, or of said D- or L- amino acid, or is deleted;

A²⁰ is Acc or Aic, or a D- or L- amino acid selected from the list of amino acids consisting of Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, and $(\text{X}^1, \text{X}^2, \text{X}^3, \text{X}^4, \text{X}^5)\text{Phe}$, or the N-methylated variant of Acc or Aic, or of said D- or L- amino acid, or is deleted;

A²¹ is Acc or Aic, or a D- or L- amino acid selected from the list of amino acids consisting of Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, and $(\text{X}^1, \text{X}^2, \text{X}^3, \text{X}^4, \text{X}^5)\text{Phe}$, or the N-methylated variant of Acc or Aic, or of said D- or L- amino acid, or is deleted;

A²² is Acc, Act, Aib, Apc, or Gly, or a D- or L- amino acid selected from the list of amino acids consisting of Ala, Aib, Abu, Val, and Nva, or the N-methylated variant of Acc, Act, Aib, Apc, or Gly, or of said D- or L- amino acid, or is deleted;

A²³ is Acc, Act, or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Ser, Thr, Ala, Abu, and Val, or the N-methylated variant of Acc, Act, or Aib, or of said D- or L- amino acid, or is deleted;

A²⁴ is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Leu, Ile, Nle, Tle, hLeu, Cha, Val, Ala, Nva, Abu, Trp, and Phe, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid, or is deleted;

A²⁵ is Acc, Aib, or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Arg, hArg, Lys, Orn, Dab, Dap, Aib, and $\text{HN-CH}((\text{CH}_2)_n\text{-N(R}^4\text{R}^5))\text{-C(O)}$, or the N-methylated variant of Acc, Aib, or Aib, or of said D- or L- amino acid, or is deleted;

A²⁶ is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of His, 2Pal, 3Pal, 4Pal, Taz, 2Thi, 3Thi, 2Fua, $\text{HN-CH}((\text{CH}_2)_n\text{-N(R}^4\text{R}^5))\text{-C(O)}$, and $(\text{X}^1, \text{X}^2, \text{X}^3, \text{X}^4, \text{X}^5)\text{-Phe}$, or the N-methylated variant of Acc, Aib, or Apc, or of said D- or L- amino acid, or is deleted;

A²⁷ is Acc or Aic, or a D- or L- amino acid selected from the list of amino acids consisting of Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, and $(\text{X}^1, \text{X}^2, \text{X}^3, \text{X}^4, \text{X}^5)\text{-Phe}$, or the N-methylated variant of Acc or Aic or of said D- or L- amino acid;

A²⁸ is Acc or Aib, a D- or L- amino acid selected from the list of amino acids consisting of Leu, Ile, Nle, Tle, hLeu, Trp, Cha, Val, Ala, Nva, Abu, and Phe, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid;

A²⁹ is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Asn, Gln, Glu, Asp, and Trp, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid;

A³⁰ is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Leu, Ile, Nle, Tle, hLeu, Trp, Cha, Val, Ala, Nva, Abu, and Phe or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid;

A³¹ is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Val, Leu, Ile, Nle, Tle, hLeu, Cha, Ala, Nva, Abu, Trp, and Phe, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid;

A³² is Acc, Act, or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Thr, Ser, Ala, Abu, Trp, DTrp, and Val, or the N-methylated variant of Acc, Act, or Aib, or of said D- or L- amino acid;

A³³ is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Arg, hArg, Lys, Orn, Dab, Dap, and $\text{HN-CH}((\text{CH}_2)_n\text{-N(R}^4\text{R}^5))\text{-C(O)}$, or the N-methylated variant of Acc, Aib, or Apc, or of said D- or L- amino acid;

A³⁴ is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Gln, Asn, Glu, Asp, or the N-methylated variant of Acc, Aib, or Apc, or of said D- or L- amino acid;

A³⁵ is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Arg, hArg, Lys, Orn, Dab, Dap, and HN-CH((CH₂)_n-N(R⁴R⁵))-C(O), or the N-methylated variant of Acc, Aib, or Apc, or of said D- or L- amino acid;

A³⁶ is Acc, Aic or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, and (X¹,X²,X³,X⁴,X⁵)Phe, or the N-methylated variant of Acc, Aic, or Apc, or of said D- or L- amino acid;

R¹ is OH or NH₂, (C₁-C₃₀)alkoxy, or NH-X⁶-CH₂-Z⁰, wherein X⁶ is a (C₁-C₁₂)hydrocarbon moiety, and Z⁰ is -H, -OH, -CO₂H or -C(O)NH₂;

R² and R³ each is, independently for each occurrence, selected from the group consisting of -H, (C₁-C₃₀)alkyl, (C₁-C₃₀)heteroalkyl, (C₁-C₃₀)acyl, (C₂-C₃₀)alkenyl, (C₂-C₃₀)alkynyl, aryl(C₁-C₃₀)alkyl, aryl(C₁-C₃₀)acyl, substituted (C₁-C₃₀)alkyl, substituted (C₁-C₃₀)heteroalkyl, substituted (C₂-C₃₀)acyl, substituted (C₂-C₃₀)alkenyl, substituted (C₂-C₃₀)alkynyl, substituted aryl(C₁-C₃₀)alkyl, and substituted aryl(C₁-C₃₀)acyl,

provided that when R² is (C₁-C₃₀)acyl, aryl(C₁-C₃₀)acyl, substituted (C₂-C₃₀)acyl, or substituted aryl(C₁-C₃₀)acyl, R³ is -H, (C₁-C₃₀)alkyl, (C₁-C₃₀)heteroalkyl, (C₂-C₃₀)alkenyl, (C₂-C₃₀)alkynyl, aryl(C₁-C₃₀)alkyl, substituted (C₁-C₃₀)alkyl, substituted (C₁-C₃₀)heteroalkyl, substituted (C₂-C₃₀)alkenyl, substituted (C₂-C₃₀)alkynyl, or substituted aryl(C₁-C₃₀)alkyl;

R⁴ and R⁵ each is, independently for each occurrence, selected from the group consisting of -H, (C₁-C₄₀)alkyl, (C₂-C₄₀)acyl, (C₁-C₃₀)alkylsulfonyl, and -C(NH)NH₂,

provided that when R⁴ is (C₁-C₄₀)acyl, (C₁-C₃₀)alkylsulfonyl, or -C(NH)NH₂, then R⁵ is -H or (C₁-C₄₀)alkyl;

n is, independently for each occurrence, 1, 2, 3, 4 or 5; and

X¹, X², X³, X⁴, and X⁵ each is, independently for each occurrence, selected from the group consisting of -H, -F, -Cl, -Br, -I, (C₁-C₁₀)alkyl, substituted (C₁-C₁₀)alkyl, aryl, substituted aryl, -OH, -NH₂, -NO₂, and -CN;

provided that:

(a) said peptide comprises at least one amino acid selected from the group consisting of:

- (i) Acc at A³, A⁶, A⁷, A⁹, A¹⁰, A¹¹, A¹², A¹⁵, A¹⁶, A¹⁷, A¹⁸, A²⁰, A²¹, A²², A²⁴, A²⁷, A²⁸, A²⁹, A³⁰, A³¹, A³², or A³⁴;
- (ii) Act at A³, A⁷, A¹², A¹³, A²², A²³, or A³²;
- (iii) Apc at A⁴, A⁷, A¹², A¹⁹, A²², A²⁵, A²⁶, A³³, A³⁵, or A³⁶;
- (iv) Aib at A⁶, A⁷, A⁹, A¹⁰, A¹¹, A¹², A¹³, A¹⁵, A¹⁶, A¹⁸, A²², A²⁹, or A³²;
- (v) Thz, Dmt, Dhp, Ktp, or Tic at A⁵, A⁸, or A¹⁴;
- (vi) (3,4,5-F)Phe or (2,3,4,5,6-F)Phe at A²⁰, A²¹, A²⁶, A²⁷, or A³⁶;

(vii) 2Fua at A²⁰, A²¹, A²⁶, or A²⁷;

(viii) Taz at A²⁰, A²¹, or A²⁶; and

(ix) 2Pal, 3Pal, 4Pal, 2Thi or 3Thi at A²⁶;

(b) if A³ - A²¹ are deleted and (i) A²² is Aib or (ii) A³⁶ is (3,4,5-F)Phe or (2,3,4,5,6-F)Phe, then A²⁷ is not 2Thi, Trp, 2Nal, or (X¹,X²,X³,X⁴,X⁵)Phe, wherein X¹ is *p*-chloro and X², X³, X⁴ and X⁵ each is -H; and

(c) each amino acid A^m of formula (I) may be deleted only if A^{m-1} is deleted, wherein m is an integer ranging in value from 4 - 26, inclusive;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, wherein:

A³ is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Ile, Leu, Nle, Tle, hLeu, Cha, Val, Ala, Nva, and Abu, or is deleted;

A⁴ is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Lys, Arg, hArg, Orn, Dab, Dap, and HN-CH((CH₂)_n-N(R⁴R⁵))-C(O), or is deleted;

A⁵ is Inc or a D- or L- amino acid selected from the list of amino acids consisting of Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, and Oic, or is deleted;

A⁶ is Acc or a D- or L- amino acid selected from the list of amino acids consisting of Glu, Asp, Gln, Asn, Lys, Arg, Orn, Dab, Dap, and hArg, or is deleted;

A⁷ is Acc, Act, Aib, Apc, or Gly, or a D- or L- amino acid selected from the list of amino acids consisting of Ala, Abu, Val, and Nva, or is deleted;

A⁸ is Inc or a D- or L- amino acid selected from the list of amino acids consisting of Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, and Oic, or is deleted;

A⁹ is Acc, Aib, or Gly or D- or L- Ala, or is deleted;

A¹⁰ is Acc or a D- or L- amino acid selected from the list of amino acids consisting of Glu, Asp, Gln, and Asn, or is deleted;

A¹¹ is Acc or a D- or L- amino acid selected from the list of amino acids consisting of Asp, Glu, Gln, and Asn, or is deleted;

A¹² is Acc, Act, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Ala, Gly, Abu, Val, and Nva, or is deleted;

A¹³ is Acc, Act, or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Ser, Thr, Ala, Abu, and Val, or is deleted;

A¹⁴ is Inc or a D- or L- amino acid selected from the list of amino acids consisting of Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, and Oic, or is deleted;

A¹⁵ is Acc or a D- or L- amino acid selected from the list of amino acids consisting of Glu, Asp, Gln, and Asn, or is deleted;

A¹⁶ is Acc or a D- or L- amino acid selected from the list of amino acids consisting of Glu, Asp, Gln, and Asn, or is deleted;

A¹⁷ is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Leu, Ile, Nle, Tle, hLeu, Cha, Val, Ala, Nva, Abu, and Phe, or is deleted;

A¹⁸ is Aib or Acc, or a D- or L- amino acid selected from the list of amino acids consisting of Asn, Gln, Glu, and Asp, or is deleted;

A¹⁹ is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Arg, hArg, Lys, Orn, Dab, Dap, and HN-CH((CH₂)_n-N(R⁴R⁵))-C(O), or is deleted;

A²⁰ is Acc or Aic, a D- or L- amino acid selected from the list of amino acids consisting of Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, and (X¹,X²,X³,X⁴,X⁵)Phe, or is deleted;

A²¹ is Acc or Aic, or a D- or L- amino acid selected from the list of amino acids consisting of Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, and (X¹,X²,X³,X⁴,X⁵)Phe, or is deleted;

A²² is Acc, Act, Aib, Apc, or Gly, or a D- or L- amino acid selected from the list of amino acids consisting of Ala, Abu, Val, and Nva, or is deleted;

A²³ is Acc, Act, or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Ser, Thr, Ala, Abu, and Val, or is deleted;

A²⁴ is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Leu, Ile, Nle, Tle, hLeu, Cha, Val, Ala, Nva, Abu, Trp, and Phe, or is deleted;

A²⁵ is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Arg, hArg, Lys, Orn, Dab, Dap, and HN-CH((CH₂)_n-N(R⁴R⁵))-C(O), or is deleted

A²⁶ is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of His, 2Pal, 3Pal, 4Pal, Taz, 2Thi, 3Thi, 2Fua, HN-CH((CH₂)_n-N(R⁴R⁵))-C(O), and (X¹,X²,X³,X⁴,X⁵-)Phe, or is deleted;

A²⁷ is Acc or Aic, or a D- or L- amino acid selected from the list of amino acids consisting of Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, and (X¹,X²,X³,X⁴,X⁵)Phe;

A²⁸ is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Leu, Ile, Nle, Tle, hLeu, Trp, Cha, Val, Ala, Nva, Abu, and Phe;

A²⁹ is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Asn, Gln, Glu, Asp, and Trp;

A³⁰ is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Leu, Ile, Nle, Tle, hLeu, Trp, Cha, Val, Ala, Nva, Abu, and Phe;

A³¹ is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Val, Leu, Ile, Nle, Tle, hLeu, Cha, Ala, Nva, Abu, Trp, and Phe;

A³² is Acc, Act, or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Thr, Ser, Ala, Abu, Trp, and Val;

A³³ is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Arg, hArg, Lys, Orn, Dab, Dap, and HN-CH((CH₂)_n-N(R⁴R⁵))-C(O);

A³⁴ is Acc, Aib, Apc, or Glu, or a D- or L- amino acid selected from the list of amino acids consisting of Gln, Asn, and Asp;

A³⁵ is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Arg, hArg, Lys, Orn, Dab, Dap, and HN-CH((CH₂)_n-N(R⁴R⁵))-C(O); and

A³⁶ is Acc, Aic, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, and (X¹,X²,X³,X⁴,X⁵)Phe;

or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 2, wherein:

A³ is Ile, Leu, Nle, Tle, hLeu, Cha, Val, Ala, Nva, Abu, Acc, or Aib, or is deleted;

A⁴ is Lys, Arg, hArg, Orn, Dab, Dap, Apc, Aib, Acc, or HN-CH((CH₂)_n-N(R⁴R⁵))-C(O), or is deleted;

A⁵ is Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, Oic, or Inc, or is deleted;

A⁶ is Glu, Asp, Gln, Asn, Lys, Arg, Orn, Dab, Dap, hArg, or Acc, or is deleted;

A⁷ is Ala, Aib, Gly, Abu, Val, Nva, Apc, Act, or Acc, or is deleted;

A⁸ is Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, Oic, or Inc, or is deleted;

A⁹ is Gly, Ala, Aib, or Acc, or is deleted;

A¹⁰ is Glu, Asp, Gln, Asn, or Acc, or is deleted;

A¹¹ is Asp, Glu, Gln, Asn, or Acc, or is deleted;

A¹² is Ala, Aib, Gly, Abu, Val, Nva, Apc, Act, or Acc, or is deleted;

A¹³ is Ser, Thr, Aib, Act, Ala, Acc, Abu, or Val, or is deleted;

A¹⁴ is Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, Oic, or Inc, or is deleted;

A¹⁵ is Glu, Asp, Gln, Asn, or Acc, or is deleted;

A¹⁶ is Glu, Asp, Gln, Asn, or Acc, or is deleted;

A¹⁷ is Leu, Ile, Nle, Tle, hLeu, Cha, Val, Ala, Nva, Abu, Acc, Aib, or Phe, or is deleted;

A¹⁸ is Asn, Gln, Glu, Asp, Aib, or Acc, or is deleted;

A¹⁹ is Arg, hArg, Lys, Orn, Dab, Dap, Apc, Aib, Acc, or HN-CH((CH₂)_n-N(R⁴R⁵))-C(O), or is deleted;

A²⁰ is Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, (X¹,X²,X³,X⁴,X⁵)Phe, Acc, or Aic, or is deleted;

A²¹ is Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, (X¹,X²,X³,X⁴,X⁵)Phe, Acc, or Aic, or is deleted;

A²² is Ala, Aib, Gly, Abu, Val, Nva, Apc, Act, Acc, or N-Me-Ala, or is deleted;

A²³ is Ser, Thr, Aib, Act, Ala, Acc, Abu, Val, or DTrp, or is deleted;

A²⁴ is Leu, Ile, Nle, Tle, hLeu, Cha, Val, Ala, Nva, Abu, Acc, Aib, Trp, or Phe, or is deleted;

A²⁵ is Arg, hArg, Lys, Orn, Dab, Dap, Apc, Aib, HN-CH((CH₂)_n-N(R⁴R⁵))-C(O), or Acc, or is deleted;

A²⁶ is His, 2Pal, D2Pal, 3Pal, 4Pal, Taz, 2Thi, 3Thi, 2Fua, Apc, Aib, Acc, HN-CH((CH₂)_n-N(R⁴R⁵))-C(O), or (X¹,X²,X³,X⁴,X⁵-)Phe, or is deleted;

A²⁷ is Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, (X¹,X²,X³,X⁴,X⁵)Phe, Acc, or Aic;

A²⁸ is Leu, Ile, Nle, Tle, hLeu, Trp, Cha, Val, Ala, Nva, Abu, Acc, Aib, or Phe;

A²⁹ is Asn, Gln, Glu, Asp, Acc, Trp, or Aib;

A³⁰ is Leu, Ile, Nle, Tle, hLeu, Trp, Cha, Val, Ala, Nva, Abu, Acc, Aib, or Phe;

A³¹ is Val, Leu, Ile, Nle, Tle, hLeu, Cha, Ala, Nva, Abu, Acc, Aib, Trp, or Phe;

A³² is Thr, Ser, Aib, Act, Ala, Acc, Abu, Trp, DTrp, or Val;

A³³ is Arg, hArg, Lys, Orn, Dab, Dap, Apc, Aib, HN-CH((CH₂)_n-N(R⁴R⁵))-C(O), or Acc;

A³⁴ is Gln, Asn, Glu, Asp, Acc, Aib, or Apc;

A³⁵ is Arg, hArg, Lys, Orn, Dab, Dap, Apc, Aib, HN-CH((CH₂)_n-N(R⁴R⁵))-C(O), or Acc;

and

A³⁶ is Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, (X¹,X²,X³,X⁴,X⁵)Phe, Acc, Aic, or Apc; or

a pharmaceutically acceptable salt thereof.

4. A compound according to claim 3, wherein:

A³ is Ile, Leu, Nle, Val, Acc, or Aib, or is deleted;

A⁴ is Lys, Arg, hArg, Orn, or Apc, or is deleted;

A⁵ is Pro, Thz, Dmt, 4Hyp, or 3Hyp, or is deleted;

A⁶ is Glu, Asp, Gln, or Acc, or is deleted;

A⁷ is Ala, Aib, Abu, Act, or Acc, or is deleted;

A⁸ is Pro, Thz, Dmt, 4Hyp, or 3Hyp, or is deleted;

A⁹ is Gly, Aib, or Acc, or is deleted;

A¹⁰ is Glu, Asp, Gln, or Acc or is deleted;

A¹¹ is Asp, Glu, Asn, or Acc or is deleted;

A¹² is Ala, Aib, Act, or Acc, or is deleted;

A¹³ is Ser, Thr, Aib, Act, or Acc, or is deleted;

A¹⁴ is Pro, Thz, Dmt, 4Hyp, or 3Hyp, or is deleted;

A¹⁵ is Glu, Asp, Gln, or Acc, or is deleted;

A¹⁶ is Glu, Asp, Gln, or Acc or is deleted;

A¹⁷ is Leu, Ile, Nle, Val, Acc, or Aib, or is deleted;

A¹⁸ is Asn, Gln, Asp, Aib, or Acc or is deleted;

A¹⁹ is Arg, hArg, Lys, or Apc, or is deleted;
A²⁰ is Tyr, Phe, 2Pal, 3Pal, 4Pal, (X¹,X²,X³,X⁴,X⁵)Phe, or Acc, or is deleted;
A²¹ is Tyr, Phe, 2Pal, 3Pal, 4Pal, (X¹,X²,X³,X⁴,X⁵)Phe, or Acc, or is deleted;
A²² is Ala, Aib, Abu, or Acc, or is deleted;
A²³ is Ser, Thr, Aib, Act, or Ala, or is deleted;
A²⁴ is Leu, Ile, Nle, Val, Acc, or Aib, or is deleted;
A²⁵ is Arg, hArg, Lys, or Apc, or is deleted;
A²⁶ is His, 2Pal, D2Pal, 3Pal, 4Pal, Taz, 2Thi, 3Thi, Apc, or (X¹,X²,X³,X⁴,X⁵-)Phe, or is deleted;
A²⁷ is Tyr, Phe, 2Pal, 3Pal, 4Pal, (X¹,X²,X³,X⁴,X⁵)Phe or Acc;
A²⁸ is Leu, Ile, Nle, Val, Acc or Aib;
A²⁹ is Asn, Gln, Asp, Acc or Aib;
A³⁰ is Leu, Ile, Nle, Val, Acc or Aib;
A³¹ is Val, Leu, Ile, Ala, Acc or Aib;
A³² is Thr, Ser, Aib, Act or Acc;
A³³ is Arg, hArg, Lys or Apc;
A³⁴ is Gln, Asn, Glu, Aib or Apc;
A³⁵ is Arg, hArg, Lys or Apc; and
A³⁶ is Tyr, Phe, 2Pal, 3Pal, 4Pal, (X¹,X²,X³,X⁴,X⁵)Phe or Apc;
or a pharmaceutically acceptable salt thereof.

5. A compound according to claim 4, wherein:

A³ is Ile or Acc, or is deleted;
A⁴ is Lys or Apc, or is deleted;
A⁵ is Pro or is deleted;
A⁶ is Glu or Acc, or is deleted;
A⁷ is Ala, Act, or Acc, or is deleted;
A⁸ is Pro or is deleted;
A⁹ is Gly or Acc, or is deleted;
A¹⁰ is Glu or Acc, or is deleted;
A¹¹ is Asp or Acc, or is deleted;
A¹² is Ala, Act, or Acc, or is deleted;
A¹³ is Ser, Act, or Acc, or is deleted;
A¹⁴ is Pro or is deleted;
A¹⁵ is Glu or Acc, or is deleted;
A¹⁶ is Glu or Acc, or is deleted;
A¹⁷ is Leu or Acc, or is deleted;
A¹⁸ is Asn or Acc, or is deleted;

A¹⁹ is Arg or Apc, or is deleted;
A²⁰ is Tyr, (X¹,X²,X³,X⁴,X⁵)Phe, or Acc, or is deleted;
A²¹ is Tyr, (X¹,X²,X³,X⁴,X⁵)Phe, or Acc, or is deleted;
A²² is Ala, Aib, or Acc, or is deleted;
A²³ is Ser or Act, or is deleted;
A²⁴ is Leu or Acc, or is deleted;
A²⁵ is Arg or Apc, or is deleted;
A²⁶ is His, 2Pal, D2Pal, 3Pal, 4Pal, Taz, Apc, or (X¹,X²,X³,X⁴,X⁵-)Phe, or is deleted;
A²⁷ is Tyr, (X¹,X²,X³,X⁴,X⁵)Phe, or Acc;
A²⁸ is Leu, or Acc;
A²⁹ is Asn or Acc;
A³⁰ is Leu or Acc;
A³¹ is Val, Leu or Acc;
A³² is Thr, Act, or Acc;
A³³ is Arg or Apc;
A³⁴ is Gln or Apc;
A³⁵ is Arg or Apc; and
A³⁶ is Tyr, (X¹,X²,X³,X⁴,X⁵)Phe, or Apc;

or a pharmaceutically acceptable salt thereof.

6. A compound according to claim 5, wherein:

Acc is, independently for each occurrence, A5c or A6c; and

(X¹,X²,X³,X⁴,X⁵)Phe is, independently for each occurrence, (3,4,5-F)Phe or (2,3,4,5,6-F)Phe; or

a pharmaceutically acceptable salt thereof.

7. A compound according to claim 6, wherein:

A³ is Ile or is deleted;

A⁴ is Lys or is deleted;

A⁶ is Glu or is deleted;

A⁷ is Ala or is deleted;

A⁹ is Gly or is deleted;

A¹⁰ is Glu or is deleted;

A¹¹ is Asp or is deleted;

A¹² is Ala or is deleted;

A¹³ is Ser or is deleted;

A¹⁴ is Pro or is deleted;

A¹⁵ is Glu or is deleted;

A¹⁶ is Glu or is deleted;

A¹⁷ is Leu or is deleted;
 A¹⁸ is Asn or is deleted;
 A¹⁹ is Arg or is deleted;
 A²⁰ is Tyr or is deleted;
 A²¹ is Tyr or is deleted;
 A²² is Ala, Aib, or A5c, or is deleted;
 A²³ is Ser or is deleted;
 A²⁴ is Leu or A6c;
 A²⁵ is Arg;
 A²⁶ is His, 2Pal, D2Pal, 3Pal, 4Pal, or Taz;
 A²⁷ is Tyr or (3,4,5-F)Phe;
 A²⁸ is Leu, or A6c;
 A²⁹ is Asn;
 A³⁰ is Leu or A6c;
 A³¹ is Val, Leu, A5c or A6c;
 A³² is Thr;
 A³³ is Arg;
 A³⁴ is Gln; and
 A³⁶ is Tyr;

or a pharmaceutically acceptable salt thereof.

8. A compound according to claim 6, wherein said compound is according to the formula:

((2,3,4,5,6-F)Phe ²⁰)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 31)
((2,3,4,5,6-F)Phe ²¹)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 32)
Ac-((2,3,4,5,6-F)Phe ²⁶)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 33)
Ac-((2,3,4,5,6-F)Phe ²⁶)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 34)
((2,3,4,5,6-F)Phe ²⁶)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 35)
Ac-((2,3,4,5,6-F)Phe ²⁷)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 36)
Ac-((2,3,4,5,6-F)Phe ²⁷)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 37)
((2,3,4,5,6-F)Phe ²⁷)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 38)
Ac-((2,3,4,5,6-F)Phe ³⁶)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 39)
Ac-((2,3,4,5,6-F)Phe ³⁶)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 40)
((2,3,4,5,6-F)Phe ³⁶)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 41)
((3,4,5-F)Phe ²⁰)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 42)
((3,4,5-F)Phe ²¹)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 43)
Ac-((3,4,5-F)Phe ²⁶)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 44)
Ac-((3,4,5-F)Phe ²⁶)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 45)

((3,4,5-F)Phe ²⁶)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 46)
Ac-((3,4,5-F)Phe ²⁷)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 15)
Ac-((3,4,5-F)Phe ²⁷)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 47)
((3,4,5-F)Phe ²⁷)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 12)
Ac-((3,4,5-F)Phe ³⁶)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 48)
Ac-((3,4,5-F)Phe ³⁶)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 49)
((3,4,5-F)Phe ³⁶)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 50)
Ac-(D2Pal ²⁶)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 26)
Ac-(2Pal ²⁶)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 27)
Ac-(2Pal ²⁶ , Leu ³¹)hPPY(24-36)NH ₂ ;	(SEQ ID NO. 18)
Ac-(3Pal ²⁶)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 14)
(3Pal ²⁶)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 5)
Ac-(3Pal ²⁶ , Leu ³¹)hPPY(24-36)NH ₂ ;	(SEQ ID NO. 16)
Ac-(4Pal ²⁶)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 13)
Ac-(4Pal ²⁶ , Leu ³¹)hPPY(24-36)NH ₂ ;	(SEQ ID NO. 17)
Ac-(A5c ²²)hPYY(22-36)NH ₂	(SEQ ID NO. 4)
Ac-(A5c ³¹)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 24)
Ac-(A5c ³¹)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 51)
(A5c ³¹)hPYY(3-36)NH ₂	(SEQ ID NO. 3)
(A6c ¹⁰)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 52)
(A6c ¹¹)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 53)
(A6c ¹²)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 54)
(A6c ¹³)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 55)
(A6c ¹⁵)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 56)
(A6c ¹⁶)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 57)
(A6c ¹⁷)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 58)
(A6c ¹⁸)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 59)
(A6c ²⁰)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 60)
(A6c ²¹)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 61)
Ac-(A6c ²²)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 62)
(A6c ²²)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 63)
Ac-(A6c ²⁴)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 25)
Ac-(A6c ²⁴)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 64)
(A6C ²⁴)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 10)
Ac-(A6c ²⁴ , Leu ³¹)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 28)
Ac-(A6c ²⁷)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 65)
Ac-(A6c ²⁷)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 66)

(A6c ²⁷)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 67)
Ac-(A6c ²⁸)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 23)
Ac-(A6c ²⁸)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 68)
(A6c ²⁸)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 8)
Ac-(A6c ²⁸ , Leu ³¹)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 29)
Ac-(A6c ²⁹)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 69)
Ac-(A6c ²⁹)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 70)
(A6c ²⁹)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 71)
(A6c ³)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 72)
Ac-(A6c ³⁰)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 22)
Ac-(A6c ³⁰)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 73)
(A6c ³⁰)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 9)
Ac-(A6c ³¹)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 21)
Ac-(A6c ³¹)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 30)
(A6c ³¹)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 74)
Ac-(A6c ³²)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 75)
Ac-(A6c ³²)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 76)
(A6c ³²)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 77)
(A6c ⁶)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 78)
(A6c ⁷)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 79)
(A6c ⁹)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 80)
(Act ¹²)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 81)
(Act ¹³)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 82)
Ac-(Act ²³)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 83)
(Act ²³)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 84)
Ac-(Act ³²)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 85)
Ac-(Act ³²)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 86)
(Act ³²)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 87)
(Act ⁷)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 88)
Ac-(Aib ²²)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 89)
(Aib ²²)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 11)
(Apc ¹⁹)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 90)
Ac-(Apc ²⁵)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 91)
Ac-(Apc ²⁵)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 92)
(Apc ²⁵)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 93)
Ac-(Apc ²⁶)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 94)
Ac-(Apc ²⁶)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 95)

(Apc ²⁶)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 96)
Ac-(Apc ³³)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 97)
Ac-(Apc ³³)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 98)
(Apc ³³)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 99)
Ac-(Apc ³⁴)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 100)
Ac-(Apc ³⁴)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 101)
(Apc ³⁴)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 102)
Ac-(Apc ³⁵)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 103)
Ac-(Apc ³⁵)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 104)
(Apc ³⁵)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 7)
Ac-(Apc ³⁶)hPYY(22-36)NH ₂ ;	(SEQ ID NO. 105)
Ac-(Apc ³⁶)hPYY(24-36)NH ₂ ;	(SEQ ID NO. 106)
(Apc ³⁶)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 107)
(Apc ⁴)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 108)
(Taz ²⁶)hPYY(3-36)NH ₂ ;	(SEQ ID NO. 6)
Ac-(Taz ²⁶)hPYY(22-36)NH ₂ ; or	(SEQ ID NO. 20)
Ac-(Taz ²⁶ , Leu ³¹)hPPY(24-36)NH ₂ ;	(SEQ ID NO. 19)

or a pharmaceutically acceptable salt thereof.

9. A compound according to claim 8, wherein said compound is according to the formula:

[A5C ³¹]hPYY(3-36)NH ₂	(SEQ ID NO. 3)
Ac-[A5C ²²]hPYY(22-36)NH ₂	(SEQ ID NO. 4)
[3Pal ²⁶]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 5)
[Taz ²⁶]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 6)
[Apc ³⁵]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 7)
[A6C ²⁸]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 8)
[A6C ³⁰]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 9)
[A6C ²⁴]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 10)
[Aib ²²]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 11)
[((3,4,5-F)Phe) ²⁷]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 12)
Ac-[4Pal ²⁶]hPYY(22-36)NH ₂ ;	(SEQ ID NO. 13)
Ac-[3Pal ²⁶]hPYY(22-36)NH ₂ ;	(SEQ ID NO. 14)
Ac-[((3,4,5-F)Phe) ²⁷]hPYY(22-36)NH ₂ ;	(SEQ ID NO. 15)
Ac-(3Pal ²⁶ , Leu ³¹)hPPY(24-36)NH ₂ ;	(SEQ ID NO. 16)
Ac-(4Pal ²⁶ , Leu ³¹)hPPY(24-36)NH ₂ ;	(SEQ ID NO. 17)
Ac-(2Pal ²⁶ , Leu ³¹)hPPY(24-36)NH ₂ ;	(SEQ ID NO. 18)
Ac-(Taz ²⁶ , Leu ³¹)hPPY(24-36)NH ₂ ;	(SEQ ID NO. 19)

Ac-[Taz ²⁶]hPYY(22-36)NH ₂ ;	(SEQ ID NO. 20)
Ac-[A6c ³¹]hPYY(22-36)NH ₂ ;	(SEQ ID NO. 21)
Ac-[A6c ³⁰]hPYY(22-36)NH ₂ ;	(SEQ ID NO. 22)
Ac-[A6c ²⁸]hPYY(22-36)NH ₂ ;	(SEQ ID NO. 23)
Ac-[A5c ³¹]hPYY(22-36)NH ₂ ;	(SEQ ID NO. 24)
Ac-[A6C ²⁴]hPYY(22-36)NH ₂ ;	(SEQ ID NO. 25)
Ac-[D2Pal ²⁶]hPYY(22-36)NH ₂ ;	(SEQ ID NO. 26)
Ac-[2Pal ²⁶]hPYY(22-36)NH ₂ ;	(SEQ ID NO. 27)
Ac-[A6C ²⁴ , Leu ³¹]hPYY(24-36)NH ₂ ;	(SEQ ID NO. 28)
Ac-[A6C ²⁸ , Leu ³¹]hPYY(24-36)NH ₂ ; or	(SEQ ID NO. 29)
Ac-[A6C ³¹]hPYY(24-36)NH ₂ ;	(SEQ ID NO. 30)

or a pharmaceutically acceptable salt thereof.

10. A compound according to claim 9, wherein said compound is:

[A5C ³¹]hPYY(3-36)NH ₂	(SEQ ID NO. 3)
[3Pal ²⁶]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 5)
[Taz ²⁶]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 6)
[A6C ²⁸]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 8)
[A6C ²⁴]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 10)
[Aib ²²]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 11)
[((3,4,5-F)Phe) ²⁷]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 12)
Ac-[4Pal ²⁶]hPYY(22-36)NH ₂ ;	(SEQ ID NO. 13)
Ac-[3Pal ²⁶]hPYY(22-36)NH ₂ ;	(SEQ ID NO. 14)
Ac-(3Pal ²⁶ , Leu ³¹)hPPY(24-36)NH ₂ ; or	(SEQ ID NO. 16)
Ac-(4Pal ²⁶ , Leu ³¹)hPPY(24-36)NH ₂ ;	(SEQ ID NO. 17)

or a pharmaceutically acceptable salt thereof.

11. A compound according to claim 9, wherein said compound is:

[A5C ³¹]hPYY(3-36)NH ₂	(SEQ ID NO. 3)
[3Pal ²⁶]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 5)
[Taz ²⁶]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 6)
[Apc ³⁵]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 7)
[A6C ²⁸]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 8)
[A6C ²⁴]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 10)
[Aib ²²]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 11)
Ac-[4Pal ²⁶]hPYY(22-36)NH ₂ ;	(SEQ ID NO. 13)
Ac-[3Pal ²⁶]hPYY(22-36)NH ₂ ;	(SEQ ID NO. 14)
Ac-(3Pal ²⁶ , Leu ³¹)hPPY(24-36)NH ₂ ; or	(SEQ ID NO. 16)
Ac-(4Pal ²⁶ , Leu ³¹)hPPY(24-36)NH ₂ ;	(SEQ ID NO. 17)

or a pharmaceutically acceptable salt thereof.

12. A compound according to claim 9, wherein said compound is:

[A5C ³¹]hPYY(3-36)NH ₂	(SEQ ID NO. 3)
[3Pal ²⁶]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 5)
[A6C ²⁸]hPYY(3-36)NH ₂ ;	(SEQ ID NO. 8)
[A6C ²⁴]hPYY(3-36)NH ₂ ; or	(SEQ ID NO. 10)
Ac-[4Pal ²⁶]hPYY(22-36)NH ₂ ;	(SEQ ID NO. 13)

or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a compound according to any one of claims 1 - 12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

14. A method of decreasing excess intestinal water and electrolyte secretion in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to any one of claims 1 - 12, or a pharmaceutically acceptable salt thereof.

15. A method of regulating cell proliferation in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to any one of claims 1 - 12, or a pharmaceutically acceptable salt thereof.

16. A method of claim 15, wherein said cell is a gastrointestinal cell.

17. A method of claim 15, wherein said cell is an epithelial cell.

18. A method of augmenting nutrient transport in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to any one of claims 1 - 12, or a pharmaceutically acceptable salt thereof.

19. A method of regulating lipolysis in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to any one of claims 1 - 12, or a pharmaceutically acceptable salt thereof.

20. A method of regulating blood flow in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to any one of claims 1 - 12, or a pharmaceutically acceptable salt thereof.

21. A method of facilitating weight loss, appetite decrease, weight maintenance, treating obesity, treating diabetes, treating complications of diabetes including retinopathy, or treating cardiovascular disorders in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to any one of claims 1 - 12, or a pharmaceutically acceptable salt thereof.

22. A method according to claim 21, wherein excessive weight is a contributing factor to a disease or condition including hypertension, diabetes, dyslipidemia, cardiovascular disease, gall stones, osteoarthritis and cancers.

23. A method according to claim 22, wherein said facilitation of weight loss reduces the likelihood of such diseases or conditions or where said facilitation of weight loss comprises at least part of a treatment for such diseases or conditions.
24. A method of antagonizing the effects of PYY(3-36) in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to any one of claims 1 - 12, or a pharmaceutically acceptable salt thereof, wherein said compound is a PYY antagonist.
25. A method according to claim 24, wherein said antagonist effects in said mammal comprise facilitating weight gain, facilitating maintenance in weight, and/or facilitating appetite increase.
26. A method according to claim 25, wherein said facilitating weight gain, facilitating maintenance in weight, and/or facilitating appetite increase is indicated in a mammal having a disease or disorder, or under going a treatment, accompanied by weight loss.
27. A method according to claim 26, wherein said diseases or disorders accompanied by weight loss include anorexia, bulimia, cancer cachexia, AIDS, wasting, cachexia, and wasting in frail elderly.
28. A method according to claim 26, wherein said treatment accompanied by weight loss comprises chemotherapy, radiation therapy, temporary or permanent immobilization, or dialysis.